A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 12, 2015

Primary Completion Date

December 24, 2020

Study Completion Date

December 24, 2020

Conditions
Hematologic Neoplasms
Interventions
DRUG

CC-90002

DRUG

Rituximab

Trial Locations (13)

28040

Hospital Universitario Fundacion Jimenez Diaz, Madrid

28041

Hospital 12 de Octubre, Madrid

37007

Hospital Universitario de Salamanca, Salamanca

39008

Hospital Marques de Valdecilla, Santander

46009

Hospital de la Fe, Valencia

78229

South Texas Accelerated Research Therapeutics, San Antonio

85258

Scottsdale Healthcare Research Institute, Scottsdale

85724

University of Arizona Cancer Center, Tucson

94143-1270

University of California San Francisco, San Francisco

06520-8073

Yale University School of Medicine, New Haven

08916

Hospital Universitari Germans Trias i Pujol Can Ruti, Badalona (Barcelona)

08035

Hospital Val d'Hebron, Barcelona

08907

Duran i Reynals Institut Catala d'Oncologia, Barcelona

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY